Trial Profile
Clinical study of recombinant human endostatin in deferent time combined with paclitaxel and cisplatin in treatment of advanced none-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Cisplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics; Therapeutic Use
- 29 Jul 2014 Status changed from not yet recruiting to completed as reported by Chinese Clinical Trial Register
- 25 Jul 2012 New trial record